Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDB-2914 for Prevention of Follicular Rupture
NCT01107093Phase 2Completed
- Sponsor
- HRA Pharma
- Start
- May 2008
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in pregnancy comparing CDB-2914 with Placebo (2 arms). Primary endpoint: Inhibition of follicular rupture. Started May 2008; status: completed.
02
Drugs
ulipristal
03
Conditions
pregnancy
Beyond the preview
Go deeper on NCT01107093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01107093.